Dimensional Fund Advisors LP Has $44.10 Million Position in Incyte Co. (INCY)

Dimensional Fund Advisors LP trimmed its position in Incyte Co. (NASDAQ:INCY) by 13.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 377,859 shares of the biopharmaceutical company’s stock after selling 60,622 shares during the period. Dimensional Fund Advisors LP’s holdings in Incyte were worth $44,104,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in INCY. Vanguard Group Inc. grew its stake in shares of Incyte by 11.1% during the 2nd quarter. Vanguard Group Inc. now owns 17,125,542 shares of the biopharmaceutical company’s stock worth $2,156,276,000 after acquiring an additional 1,709,685 shares in the last quarter. Capital International Investors boosted its position in Incyte by 4.0% during the second quarter. Capital International Investors now owns 6,407,197 shares of the biopharmaceutical company’s stock worth $806,730,000 after purchasing an additional 246,134 shares during the period. BB Biotech AG boosted its position in Incyte by 0.7% during the second quarter. BB Biotech AG now owns 3,514,822 shares of the biopharmaceutical company’s stock worth $442,551,000 after purchasing an additional 25,000 shares during the period. Matrix Capital Management Company LP lifted its holdings in shares of Incyte by 28.3% during the second quarter. Matrix Capital Management Company LP now owns 1,796,716 shares of the biopharmaceutical company’s stock worth $226,225,000 after buying an additional 396,716 shares in the last quarter. Finally, UBS Asset Management Americas Inc. lifted its holdings in shares of Incyte by 10.7% during the second quarter. UBS Asset Management Americas Inc. now owns 1,636,035 shares of the biopharmaceutical company’s stock worth $205,993,000 after buying an additional 158,574 shares in the last quarter. Institutional investors and hedge funds own 90.74% of the company’s stock.

In related news, EVP Vijay K. Iyengar sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $97.26, for a total value of $486,300.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Reid M. Huber sold 696 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $98.01, for a total value of $68,214.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,118 shares of company stock worth $3,968,133. Company insiders own 17.70% of the company’s stock.

A number of equities research analysts have recently weighed in on INCY shares. Raymond James Financial raised Incyte from a “market perform” rating to an “outperform” rating and set a $159.00 target price for the company in a report on Monday, September 11th. Deutsche Bank started coverage on Incyte in a report on Tuesday, December 12th. They set a “hold” rating and a $106.00 target price for the company. Argus reissued a “buy” rating and set a $150.00 target price on shares of Incyte in a report on Wednesday, September 13th. BMO Capital Markets dropped their target price on Incyte from $163.00 to $162.00 and set an “outperform” rating for the company in a report on Thursday, October 26th. Finally, Royal Bank of Canada started coverage on Incyte in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $136.00 price target for the company. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $143.11.

Shares of Incyte Co. (INCY) opened at $100.81 on Tuesday. The firm has a market capitalization of $21,270.00, a PE ratio of -126.01 and a beta of 0.74. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.81 and a current ratio of 4.82. Incyte Co. has a twelve month low of $92.91 and a twelve month high of $153.15.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.11. The company had revenue of $381.50 million for the quarter, compared to analysts’ expectations of $360.34 million. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The business’s quarterly revenue was up 41.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.19 earnings per share. research analysts anticipate that Incyte Co. will post -1.32 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.com-unik.info/2018/01/09/dimensional-fund-advisors-lp-has-44-10-million-position-in-incyte-co-incy.html.

Incyte Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit